Treatment of lambs (initial BW 28 kg) for 24 d with a combined implant containing 40 mg of trenbolone acetate (TBA) and 8 mg of estradiol (E 2 ) increased ADG 25% ( P < .05, n = 8 ) and feed efficiency 23% ( P < .05, n = 2 ) compared with unimplanted lambs. By d 3 following implantation, sera from wethers implanted with TBA + E 2 showed 32% (307 vs 233 ng/mL) increases ( P < .001, n = 8 ) in IGF-I concentration compared with sera from unimplanted wethers. This increase was maintained throughout the entire 24-d study. Steady-state hepatic IGF-I mRNA levels were increased approximately 150% in implanted lambs compared with unimplanted lambs ( P < .05, n = 4). These data suggest that liver may be the source of at least part of the increased circulating IGF-I in TBA + E 2 -implanted sheep. In steers implanted with Revalor-S (120 mg of TBA and 24 mg of E 2 ) for 40 d, the steady-state concentration of IGF-I mRNA in the longissimus muscle was 68% greater than in the longissimus muscle of unimplanted steers ( P = .013, n = 4). Consequently, increased local production of IGF-I by muscle tissue may play a role in increasing circulating IGF-I concentrations as well as an autocrine or paracrine role in stimulating muscle growth in steers implanted with Revalor-S.
Introduction
Revalor-S, an implant containing trenbolone acetate ( TBA) and estradiol ( E 2 ) , increases ADG, feed efficiency, longissimus muscle area, and carcass protein in feedlot cattle (Bartle et al., 1992; Johnson et al., 1996a) . Recent reports of elevated IGF-I concentrations in implanted steers have raised the possibility that IGF-I may be involved in this enhanced performance (Johnson et al., 1996b) . Although circulating IGF-I concentrations are increased by 21 d after implantation, the time course of this increase is not known (Johnson et al., 1996b) , and it is not clear whether increased circulating IGF-I results from decreased clearance rate or from increased production by the liver or other tissues such as muscle. In addition to potentially contributing to increased circulating IGF-I concentrations, IGF-I produced in muscle may act via autocrine or paracrine mechanisms to stimulate muscle growth (Grant et al., 1991 (Grant et al., , 1993 Jennische and Matejka, 1992; Coleman et al., 1994; Czerwinski et al., 1994; Brameld et al., 1996) . Thus, it is important to know whether TBA + E 2 implantation affects local production of IGF-I in muscle tissue. In this study, we present data that provide answers to some of these questions.
Materials and Methods
The objectives of the current study were to examine the changes in circulating IGF-I concentration at various times after implantation of wethers with a combined TBA and E 2 implant and to compare the steady-state concentrations of hepatic IGF-I mRNA in TBA + E 2 -implanted and unimplanted sheep. Additionally, we compared the steady-state IGF-I concentration in longissimus muscle tissues from Revalor-Simplanted steers and unimplanted steers.
Animals. All experimental procedures performed in this study were approved by the University of Minnesota's Animal Care Committee. Sixteen crossbred wether lambs (initial weight 28 kg) were assigned to one of four pens (four lambs/pen). Pens were randomly assigned to one of two treatments (two pens/treatment): steroid-implanted (40 mg of TBA + 8 mg of E 2 , in a combined implant) and unimplanted. Lambs were allowed to consume an 85% concentrate diet (Table 1 ) ad libitum for the entire study. Lambs were implanted on d 0 and were slaughtered on d 24. On d 0, 3, 7, 10, 14, 19 , and 24, blood samples were obtained from the jugular vein, and serum was harvested and stored for use in analysis of circulating IGF-I. On d 24, the lambs were slaughtered, and liver samples from four randomly selected, implanted and four randomly selected, unimplanted lambs were collected and frozen for use in isolation of total hepatic RNA. Bovine muscle samples analyzed for IGF-I mRNA in this study were from steers used in the serial slaughter experiment described by Johnson et al. (1996a) . Briefly, crossbred yearling steers (394.1 kg) were assigned to one of four pens (16 steers/pen). Subsequently, pens were randomly assigned to one of two treatments (two pens/treatment): implanted (120 mg of TBA + 24 mg of E 2 ; Revalor-S; Hoechst-Roussel Agri-Vet, Somerville, NJ) or unimplanted (32 steers/ treatment). On d 40 of this study, eight unimplanted and eight implanted steers were slaughtered as part of the serial slaughter study. At this time, longissimus muscle samples were taken from four randomly selected, unimplanted and four randomly selected, implanted steers and frozen in liquid nitrogen for use in RNA preparation and analysis. The decision to use muscle samples from steers rather than taking muscle samples from the sheep used in the first part of this study was based on the fact that we had extensive carcass and muscle protein accretion data from the steers from which the samples were obtained (Johnson et al., 1996a) . These data documented more rapid and efficient muscle growth in Revalor-S-implanted steers than in unimplanted steers. Unfortunately, liver samples from these steers were not available.
Iodination of IGF-I. Human recombinant IGF-I ( R &
D Systems, Minneapolis, MN) was radioiodinated with the iodogen procedure (Frey et al., 1994) . The specific activity of iodinated preparations typically ranged between 200 and 300 mCi/mg, and over 90% of the radiolabel was trichloracetic acid-precipitable.
Insulin-Like Growth Factor-I Radioimmunoassay. Serum IGF-I concentrations were measured using a heterologous RIA (Frey et al., 1994) . Sera were extracted with .1 M glycyl-glycine (pH 2.0) in a 1:1 ratio at 37°C for 48 h to reduce the IGF binding protein ( BP) interference in the IGF-I RIA (Plaut et al., 1991 , Johnson et al., 1996b . In all cases, final pH of the extraction mixture was between 3.6 and 3.8. Glycyl-glycine-extracted sera samples were diluted 1: 250 (vol/vol) sodium azide, pH 7.5), and .1 mL was added to the RIA. A rabbit anti-human IGF-I polyclonal antibody (UB3-189 from NHPP of NIDDK) was added to the tubes at a 1:10,000 dilution and incubated for 72 h at 4°C. Approximately 12,000 cpm of 125 I IGF-I was added and incubated for 24 h at 4°C, after which time the bound and free IGF-I were separated by addition of a pre-precipitated goat antirabbit second antibody (1:5 dilution) in RIA buffer. The tubes were incubated for 4 h at 4°C, 2 mL of RIA buffer without BSA was added, and then the tubes were centrifuged at 1,800 × g for 20 min at 4°C. The supernatant was aspirated, and the radioactivity was measured in a gamma counter. Intra-and interassay coefficients of variation were 3.4 and 8.1%, respectively. Recovery of added IGF-I was 90% (Frey et al., 1994; Johnson et al., 1996b) .
Northern Hybridization. Total RNA was isolated using the single step guanidinium thiocyanate procedure (Chomczynski and Sacchi, 1987) . Total RNA (75 mg ) was denatured (24 mM HEPES, 6 mM sodium acetate, 1.2 mM EDTA, 50% deionized formamide, and 2.2 M formaldehyde) and fractionated on a 1.2% agarose gel containing 2.2 M formaldehyde in 20 mM phosphate buffer, pH 7.0. The RNA was transferred to Gene Screen (Du Pont NEN, Boston, MA) and hybridized with a 32 P-labeled ovine IGF-I probe produced using PCR. The plasmid containing ovine IGF-I was kindly provided by E. A. Wong (clone A21) (Wong et al., 1988) . Primers were designed to amplify a 478-bp sequence within the clone. The forward primer was 5′-TATTTCAACAAGCCCACG-3′, and the reverse primer was 5′-AACAGCAATCTACCAACTCC-3′. Before PCR radiolabeling, optimal PCR conditions were determined using a PCR optimization kit (OptiPrime; Stratagene, La Jolla, CA). Amplification reactions (50 mL ) conducted in the absence of radioactivity contained .1 to 50 ng of plasmid template, .6 mM of the forward and reverse primers, 50 mM of each deoxynucleotide, and 2.5 units of Ampli-Taq DNA polymerase (Perkin-Elmer, Branchburg, NJ) in an amplification buffer (10 mM Tris-HCl, pH 8.8; 3.5 mM MgCl 2 ; 75 mM KCl). The PCR radiolabeling conditions were modified as described previously (Mertz and Rashtchian, 1994) . Reactions (20 mL ) contained 10 ng of plasmid template, .6 mM of the forward and reverse primers, 2 mM each of dATP, dGTP, and dTTP, .825 mM [ 32 P]dCTP (3,000 Ci/mmol), and 1 unit of Ampli-Taq in the PCR buffer. The PCR thermocycling was performed as follows: one cycle of 94°C/3 min and 50°C/2 min; 30 cycles of 72°C/1.5 min, 94°C/1 min, and 50°C/1 min; with a final extension at 72°C/8 min. To assess the size of the amplicon, PCR was performed in the presence of unlabeled nucleotides, and amplification products were fractionated on a 1.2% TAE agarose gel followed by ethidium bromide staining. For production of labeled probe, [ 32 P]dCTP was included in the PCR reaction. Incorporation of [ 32 P]dCTP into probe was determined using TLC plates. Between 50 and 70% of the [ 32 P]dCTP added to the PCR reaction mixture was routinely incorporated into the PCR product. A Sephadex G-50 column was used to remove the unincorporated radionucleotide before hybridization. Hybridization ( 1 × 10 6 cpm/mL) was for 18 h at 42°C in .05 M NaPO 4 , pH 6.8, 50% formamide, 1× Denhardt's solution, .1% SDS, 4× SSC (.6 M NaCl, .06 M Na citrate, pH 7.0), .5 mg sodium pyrophosphate/mL. The transfer was washed once in 1× SSC, .1% SDS at 55°C for 15 min and twice in .1× SSC, .1% SDS at 60°C for 15 min each time, and the extent of hybridization was visualized using autoradiography.
Transfers were then stripped according to the manufacturer's instructions (Du Pont NEN) and reprobed with a [ 32 P]-glyceraldehyde phosphate dehydrogenase ( GAPDH) probe to assess RNA loading in each lane. The GAPDH probe was produced by random priming of a commercially available GAPDH cDNA (mouse GAPDH cDNA from Ambion Inc., Catalog #7330) template. The signal intensities of the IGF-I and the GAPDH mRNA were measured by scanning densitometry of autoradiograms, and the signal intensity of IGF-I mRNA in each lane was corrected for differences in RNA load by normalizing to the GAPDH signal in the same lane.
Ribonuclease Protection Assays for Muscle IGF-I.
Briefly, 30 mg of total muscle tissue RNA was hybridized with 5 × 10 5 cpm of a bovine IGF-I antisense cRNA probe at 45°C overnight in hybridization solution (80% deionized formamide, 100 mM sodium citrate, 300 mM sodium acetate, pH 6.4, 1 mM EDTA). Following hybridization, samples were treated with a mixture of RNase A and T1 for 30 min at 37°C. Protected RNA fragments were precipitated, dissolved in loading buffer, denatured at 90°C for 5 min, and resolved by electrophoresis on a 5% acrylamide, 8 M urea denaturing gel. The gel was then dried and subjected to autoradiography using Kodak x-omat film. Bovine IGF-I cDNA was prepared in our laboratory by RT-PCR from bovine liver RNA. Primers were designed to amplify a 348-bp sequence (209−556) and to add the T3 ( 5 ′ end) and T7 ( 3 ′ end) RNA polymerase promoter sequences to the amplified sequence. The forward primer was 5′-TTATTAACCCT-CACTAAAGGGAAGGCTTTTATTTCAACAAGCCC-3′, and the reverse primer was 5′-TAATACGACTCAC-TATAGGGCGATTTTGGTAGGTCTTCTGGTG-3′. The sequence of the IGF-I cDNA amplicon was verified to be a 100% match with the appropriate section of the published bovine IGF-I cDNA. The amplicon was then cut with StyI to yield a 180-bp cDNA that was used to produce the IGF-I cRNA anitsense probe. To control for variation in RNA loading in the ribonuclease protection assay, a labeled cRNA fragment of cyclophilin (human cyclophilin cDNA from Ambion Inc., Catalog # 7550) was included in each hybridization reaction and the cyclophilin signal intensity was used to normalize the IGF-I signal intensities. The relative signal intensities of the protected IGF-I and cyclophilin fragment bands were measured using a Bio-Rad GS-670 imaging densitometer (Bio-Rad, Hercules, CA) in conjunction with the Bio-Rad Molecular Analyst™ software.
Statistical Analysis. Data were analyzed by analysis of variance using the General Linear Model procedure of PC SAS™ (1989) Release 6.04 (SAS, 1989) . In cases in which main effects were significant, differences between means for preplanned comparisons were tested using Fisher's LSD test.
Results
Performance of Unimplanted and Implanted Wethers and Steers. Implantation of sheep increased ADG by 25% ( P < .05) and feed efficiency by 23% ( P < .05) compared with unimplanted lambs (Table 2) . Dry matter intake was not different between implanted and unimplanted wethers ( Table 2) . Implantation of steers increased ADG by 18% ( P < .001) and feed efficiency by 13% ( P < .01) compared with unimplanted steers (Johnson et al., 1996a) . As for wethers, dry matter intake was not different between implanted and unimplanted steers (Johnson et al., 1996a) . These increases in rate of gain and feed efficiency establish the efficacy of the implant in sheep and steers.
Time Course of the Increase in Serum IGF-I Concentration in Implanted Wethers. On d 3 and 10 after
implantation, serum IGF-I concentrations in implanted wethers had increased by 43 and 62% ( P < .001), respectively, relative to concentrations in sera from the same animals on d 0, and this increase was maintained throughout the 24-d duration of the study. On these same days, serum IGF-I concentrations of unimplanted wethers were not different from those on d 0. By d 3 and 10 following implantation, sera from wethers implanted with TBA/E 2 showed a 32% (307 vs 233 ng/mL) and a 51% (360 vs 238 ng/mL) increase ( P < .001), respectively, in IGF-I concentration compared with sera from unimplanted wethers (Figure 1) . On d 24, sera from TBA/E 2 -implanted Figure 1 . Serum insulin-like growth factor I (IGF-I) concentration in unimplanted (CTL) and implanted (IMP) wethers at various times after implantation. The IGF-I concentrations in implanted wethers are significantly greater than in unimplanted wethers on all days except d 0 (P < .05, n = 8). Pooled SEM is 14.9 ng/mL. lambs maintained a 40% (341 vs 244 ng/mL) increase ( P < .001) in circulating IGF-I levels. Thus, circulating IGF-I concentration was increased by d 3 after implantation and was maintained at an elevated level throughout the 24-d duration of the study.
Hepatic Steady-State IGF-I mRNA Levels in Unimplanted and Implanted Wethers. Steady-state IGF-I mRNA concentrations were measured in liver samples collected on d 24. In these studies, Northern blots of total hepatic mRNA were probed with a 32 P-labeled ovine IGF-I cDNA produced by polymerase chain reaction. Forward and reverse PCR primers were designed to yield a 478-bp probe (Figure 2) . Probing of Northern blots of total hepatic RNA with this radiolabeled PCR product revealed IGF-I mRNA transcripts at 7.6, 4, 3.5, 1.3, and 1.1 kb (Figure 3 ). Densitometric analysis of autoradiograms probed with radiolabeled IGF-I cDNA and correction for loading differences showed that steady-state hepatic IGF-I mRNA levels were 150% higher in implanted than in unimplanted wethers (Figure 4) . Steady-state concentrations of all of the detected IGF-I mRNA transcripts were increased in total RNA isolated from implanted wethers. Thus, TBA/E 2 does not seem to differentially regulate the steady-state concentrations of the IGF-I mRNA transcripts detected in liver. These data show that steady-state levels of hepatic IGF-I mRNA are increased by TBA/E 2 implantation and suggest that liver may be the source of at least part of the increased circulating IGF-I in steroid-implanted animals.
Steady-State Concentration of IGF-I mRNA in the Longissimus Muscle of Implanted and Unimplanted
Steers. Several studies have established that IGF-I is produced locally in muscle tissue and that it may function in an autocrine or paracrine manner to stimulate muscle growth. Consequently, it was of interest to determine whether Revalor-S implantation increased steady-state concentration of IGF-I mRNA Figures 5 and 6 show the results of ribonuclease protection assays of total RNA isolated from the longissimus muscles of implanted and unimplanted steers. Results showed that IGF-I mRNA concentration was 68% higher in implanted than in unimplanted steers ( P = .013, n = 4).
Discussion
Wethers implanted with TBA/E 2 for only 24 d demonstrated significant increases in ADG and feed efficiency. The observed increases are comparable to those reported in other studies in which sheep have been treated with implants similar to those used in this study. In addition to increased ADG and feed efficiency, wethers implanted with a combination of TBA and E 2 demonstrate increased steady-state levels of hepatic IGF-I mRNA and increased circulating concentrations of IGF-I. Circulating IGF-I concentration is increased relatively rapidly (within 3 d ) after implantation, suggesting that this potent anabolic growth factor may play a significant role in the increased growth rate and feed efficiency observed in implanted animals. Additionally, the steroid-induced increase in steady-state concentration of hepatic IGF-I mRNA indicates that increased production of IGF-I by the liver could be at least partially responsible for the increased serum IGF-I concentration observed in TBA/ E 2 -implanted wethers. This does not rule out the possibility that IGF-I from other sources, such as muscle, also contributes to elevated circulating IGF-I concentrations in implanted sheep. Additionally, in this study the dosage of TBA and E 2 per kilogram of body weight was approximately three times greater than that approved for use in steers. Consequently, because of the species and dosage differences, caution should be used in extrapolating results obtained in this study to steers. However, these data do show that treatment of a ruminant with a combined TBA + E 2 implant can increase the steady-state level of hepatic IGF-I mRNA.
Hepatic IGF-I production has generally been shown to be dependent on the circulating concentration of somatotropin. However, it is interesting to note that the preponderance of studies have failed to detect a TBA/E 2 -induced increase in circulating somatotropin concentration (Hunt et al., 1991; Hayden et al., 1992; Hongerholt et al., 1992) . Thus, TBA/E 2 treatment may increase circulating IGF-I and(or) steady state hepatic IGF-I mRNA concentrations without increasing circulating somatotropin concentration. A possible Figure 4 . Steady-state hepatic IGF-I mRNA levels in unimplanted (CTL) wethers and wethers implanted (IMP) with a combined implant containing 40 mg of trenbolone acetate and 8 mg of estradiol. Density values were normalized for differences in mRNA loading by using the signal intensity of glyceraldehyde phosphate dehydrogenase mRNA. Steady-state levels of IGF-I mRNA in implanted wethers are 150% greater than in unimplanted controls (P < .05, n = 4). Pooled SEM is 1.97. mechanism for this effect may be found in a report that estradiol increases the number and affinity of hepatic somatotropin receptors (Breier et al., 1988) . These receptor changes may make the liver more responsive to somatotropin. Alternatively, certain anabolic steroids may act directly to increase the production of IGF-I by the liver or other tissues. Recently it has been hypothesized that gonadal steroids affect IGF-I concentration at the level of the IGF-I gene and that changes in somatotropin levels represent a reaction to altered IGF-I concentrations (Borski et al., 1996) .
Our studies also have shown that Revalor-S implantation results in increased IGF-I mRNA concentration in the longissimus muscle of steers. This result is consistent with a recent report that treatment of elderly men with testosterone increases the steadystate level of IGF-I mRNA in muscle tissue (Urban et al., 1995) . As indicated previously, the muscle samples used in the current study were obtained from steers that were part of a larger serial slaughter study in which the effects of Revalor-S on performance, carcass characteristics, and circulating IGF-I concentrations were measured. Data obtained from the serial slaughter study showed that daily carcass protein accretion was 82% greater between d 0 and 40 in implanted steers compared with unimplanted steers (Johnson et al., 1996a) . Additionally, longissimus muscle area was numerically greater on d 40 and significantly greater on d 115 in implanted steers than in unimplanted steers ( P < .05) (Johnson et al., 1996a) . Because IGF-I is an extremely potent anabolic agent for skeletal muscle, increased local IGF-I levels may provide a possible mechanism for the increased muscle growth observed in Revalor-S-implanted steers. Additionally, increased production of IGF-I by muscle tissue may contribute to increases in circulating IGF-I concentrations observed in Revalor-S-implanted steers.
Although somatotropin-stimulated increases in muscle IGF-I mRNA concentration have been observed in the semitendinosus of pigs, several studies have shown that somatotropin injection does not stimulate increased IGF-I mRNA concentration in the longissimus muscle of pigs (Grant et al., 1991 (Grant et al., , 1993 Coleman et al., 1994; Brameld et al., 1996) . Thus, our observation that Revalor-S implantation increases IGF-I mRNA in the longissimus muscle of steers suggests the possibility that this increase may not be mediated by increased concentrations of circulating somatotropin. However, it also is possible that this is a species difference between cattle and pigs, so more work is necessary to unequivocally establish the role of somatotropin in the Revalor-S-induced increase in longissimus muscle IGF-I mRNA. showing the relative IGF-I mRNA levels in the longissimus muscle of steers implanted for 40 d with Revalor-S and in the longissimus muscle of unimplanted steers. All IGF-I values were normalized by using the cyclophilin signal density to adjust for loading or recovery differences between samples. Relative IGF-I mRNA levels detected in assay tubes containing various quantities of standard bovine muscle RNA showed that the RPA responded linearly to increasing quantities of IGF-I mRNA. Values shown are the average ± the standard error obtained by pooling data from four implanted and four unimplanted steers. The IGF-I mRNA concentration was 69% greater in the longissimus muscle of implanted (Implant) steers than in the longissimus muscle of unimplanted (Control) steers (P = .013, n = 4). Pooled SEM is .72.
Implications
Our results show for the first time that muscle insulin-like growth factor I mRNA levels are elevated by Revalor-S implantation of feedlot steers. These data suggest that muscle tissue may produce higher levels of insulin-like growth factor I in implanted than in unimplanted steers. Increased local production of this potent anabolic growth factor in muscle tissue of implanted steers may contribute to the enhanced muscle growth observed in these animals. These data contribute to our understanding of how anabolic steroids stimulate muscle growth.
